BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
2733245
Number of visits today
428
Number of downloads
2004220
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Ruiz-martinez A, Gong C, Wang H, Sové RJ, Mi H, Kimko H, Popel AS. Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model. PLoS Comput Biol 2022;18:e1010254. [DOI: 10.1371/journal.pcbi.1010254] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Goodin DA, Frieboes HB. Evaluation of innate and adaptive immune system interactions in the tumor microenvironment via a 3D continuum model. J Theor Biol 2023;559:111383. [PMID: 36539112 DOI: 10.1016/j.jtbi.2022.111383] [Reference Citation Analysis]
2 Furukawa N, Stearns V, Santa-Maria CA, Popel AS. The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting. Expert Opin Ther Targets 2023;:1-16. [PMID: 36657483 DOI: 10.1080/14728222.2022.2170779] [Reference Citation Analysis]
3 Butner JD, Dogra P, Chung C, Pasqualini R, Arap W, Lowengrub J, Cristini V, Wang Z. Mathematical modeling of cancer immunotherapy for personalized clinical translation. Nat Comput Sci 2022;2:785-796. [DOI: 10.1038/s43588-022-00377-z] [Reference Citation Analysis]
4 Mi H, Sivagnanam S, Betts CB, Liudahl SM, Jaffee EM, Coussens LM, Popel AS. Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic Biomarkers. Cancer Res 2022;82:4359-72. [PMID: 36112643 DOI: 10.1158/0008-5472.CAN-22-1190] [Reference Citation Analysis]
5 Cambi A, Ventre M. Collagen-Based Biomimetic Systems to Study the Biophysical Tumour Microenvironment. Cancers (Basel) 2022;14. [PMID: 36497421 DOI: 10.3390/cancers14235939] [Reference Citation Analysis]
6 Sové RJ, Verma BK, Wang H, Ho WJ, Yarchoan M, Popel AS. Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model. J Immunother Cancer 2022;10. [PMID: 36323435 DOI: 10.1136/jitc-2022-005414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345